stock downgrade

In a note to investors, the investment bank said the company is going through a transition phase, and has limited potential for near-term upside.

The investment bank, which maintained its $60 price target for the company's stock, said it is looking for signs of revenue acceleration.

The investment bank provided the updates as part of its 2017 outlook on the US life science tools and diagnostics markets.

Revenues rose thank to an increase in the company's human health business, which offset a decline in its environmental health segment.

Mizuho Securities has lowered its rating of the company to Neutral from Buy and cut the price target on its stock nearly in half to $6.50 from $12.

The investment bank said it expects that continued margin expansion will be more challenging than the company's stock price indicates.

The molecular diagnostics company said the number of Atlas instruments placed with customers under commercial agreements rose to 41 from 38 in Q4 2014.

The investment bank believes there's more risk for a downside on the company's stock than there is potential for an upside.

The investment bank said the company's stock has performed well in recent years and is now "appropriately priced."

The investment bank also raised its outlook on the life science tools sector, lowered its view of labs, and stayed steady on diagnostics.

Pages

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.